KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY

被引：0
|
作者：
Vinti, Luciana [1 ]
Daw, Stephen [2 ]
Alvarez, Constantino Sabado [3 ]
Fagioli, Franca [4 ]
Beishuizen, Auke [5 ]
Michel, Gerard [6 ]
Moleti, Maria Luisa [7 ]
Cepelova, Michaela [8 ]
Thorwarth, Anne [9 ]
Rigaud, Charlotte [10 ]
De Sabando, Diego Plaza Lopez [11 ]
Parker, Judith Landman [12 ]
Zhu, Ying [13 ]
Pillai, Pallavi [13 ]
Nahar, Akash [13 ]
Mauz-Koerholz, Christine [14 ,15 ]
机构：
[1] IRCCS Osped Pediatrico Bambino Gesu, Pediat Hematol & Oncol, Rome, Italy
[2] Univ Coll London Hosp NHS Fdn Trust, Pediat & Hematol Oncol, London, England
[3] Hosp Univ Vall Hebron, Pediat Oncol, Barcelona, Spain
[4] Osped Infantile Regina Margherita, Pathol & Child Care, Turin, Italy
[5] Princess Maxima Centrum, Hematol Malignancies, Utrecht, Netherlands
[6] CHU Marseille, Hop Timone Enfants, Pediat & Pediat Hematol, Marseille, France
[7] Univ Roma La Sapienza, Pediat Hematol & Oncol, Rome, Italy
[8] Fak Nemocnice Motole, Pediat Hematol & Oncol, Prague, Czech Republic
[9] Charite Univ Med Berlin, Campus Virchow Klinikum, Pediat Oncol & Hematol, Berlin, Germany
[10] Gustave Roussy Canc Campus, Pediat Hematol & Oncol, Villejuif, France
[11] Hosp Univ La Paz, Pediat Hematol & Oncol, Madrid, Spain
[12] Hop Enfants Armand Trousseau, Pediat, Paris, France
[13] Merck Co Inc, Med Oncol, Kenilworth, NJ USA
[14] Justus Liebig Univ Giessen, Giessen, Germany
[15] Martin Luther Univ Halle Wittenberg, Fac Med, Pediat Hematol & Oncol, Halle, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O046
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087
    Moskowitz, C.
    Zinzani, P. L.
    Fanale, M. A.
    Armand, P.
    Johnson, N.
    Ribrag, V.
    Radford, J.
    von Tresckow, B.
    Tomita, A.
    Shipp, M. A.
    Wang, Y.
    Ricart, A. D.
    Balakumaran, A.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 319 - 319
  • [22] Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
    Moskowitz, Craig H.
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie A.
    Radford, John A.
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Gustafson, Eric
    Zhang, Yinghua
    Ricart, Alejandro Daniel
    Balakumaran, Arun
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [23] Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
    Chen, Robert W.
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie
    Ribrag, Vincent
    Radford, John A.
    Tomita, Akihiro
    Shipp, Margaret Ann
    Wang, Yang
    Ricart, Alejandro Daniel
    Balakumaran, Arun
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma
    Hochberg, Jessica C.
    Basso, Jaclyn
    Klejmont, Liana
    Harrison, Lauren
    Flower, Allyson M.
    Gardenswartz, Aliza
    Shi, Qiuhu
    Gerard, Perry
    Islam, Humayan
    Cairo, Mitchell S.
    BLOOD, 2019, 134
  • [25] Reducing the Burden of Chemoradiotherapy With the Combination of Brentuximab Vedotin and Rituximab With Reduced-Toxicity Chemotherapy in Children, Adolescents, and Young Adults With Newly Diagnosed Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 17 - 18
  • [26] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Rueda, Antonio
    Armand, Philippe
    Trneny, Marek
    Feldman, Tatyana A.
    Ansell, Stephen M.
    Provencio, Mariano
    Jaeger, Ulrich
    Cohen, Jonathon B.
    Savage, Kerry J.
    Willenbacher, Wolfgang
    Sacchi, Mariana
    Sumbul, Anne
    Domenech, Eva Domingo
    BLOOD, 2017, 130
  • [27] Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
    Zhang, Zufei
    Zhang, Daping
    Guo, Wenchuan
    Fenton, Keenan
    Narayanan, Sujata
    Jain, Shweta
    Jiang, Joy
    Castellino, Sharon M.
    Kelly, Kara M.
    Cole, Peter D.
    Keller, Frank G.
    Garg, Amit
    Chia, Yen Lin
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3273 - 3281
  • [28] A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
    Armand, Philippe
    Shipp, Margaret Ann
    Kuruvilla, John
    Collins, Graham P.
    Ramchandren, Rod
    Timmerman, John
    Sumbul, Anne
    Ruisi, Mary M.
    Kato, Kazunobu
    Ansell, Stephen Maxted
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
    Katz, Deborah A.
    Morris, Joan D.
    Chu, Michael P.
    David, Kevin A.
    Thieblemont, Catherine
    Morley, Nicholas J.
    Khan, Sharif S.
    Viardot, Andreas
    Martin Garcia-Sancho, Alejandro
    Rodriguez-Garcia, Guillermo
    Bastos-Oreiro, Mariana
    Lee, Seung Tae
    Kormany, William
    Chen, Yuqi
    Wong, Hansen L.
    Anderson, Abraham A.
    Katlinskaya, Yuliya
    Avilion, Ariel A.
    Dai, Tian
    Gonzalez-Barca, Eva
    LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2063 - 2073
  • [30] Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
    Geoerger, Birgit
    Zwaan, C. Michel
    Marshall, Lynley V.
    Michon, Jean
    Bourdeaut, Franck
    Casanova, Michela
    Corradini, Nadege
    Rossato, Gianluca
    Farid-Kapadia, Mufiza
    Shemesh, Colby S.
    Hutchinson, Katherine E.
    Donaldson, Francis
    Liao, Minlei
    Caron, Hubert
    Trippett, Tanya
    LANCET ONCOLOGY, 2020, 21 (01): : 134 - 144
12345